Non-Small Cell Lung Cancer
Conditions
Interventions
Observation group:None
Sponsors
The Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Obtain the patient's written informed consent; 2. Male or female, aged >= 18 years; 3. Pathological stage IA2-IIIA NSCLC (IASLC 9th Edition); 4. Patients with stage IA2 and IA3 must have at least one high-risk factor. High-risk factors include: pathological tissue types containing high-grade components [solid pattern, micropapillary pattern, cribriform and/or complex glandular structures], vascular invasion, vascular tumor thrombus, nerve invasion, and spread through air spaces (STAS); 5. Positive for EGFR-sensitive mutations (19del and/or L858R mutation, with or without T790M mutation), which must be confirmed by tumor tissue analysis; 6. After R0 resection of lung cancer; 7. Have received furmonertinib treatment.
Exclusion criteria
Exclusion criteria: 1. Prior receipt of treatment with other EGFR-TKIs; 2. History of other malignant tumors, or concurrent other malignant tumors at present (except for malignant tumors that have undergone radical resection and have not recurred for 5 years after surgery, such as carcinoma in situ of the cervix, basal cell carcinoma of the skin, and papillary thyroid carcinoma, etc.); 3. Current pregnancy or lactation; 4. Other conditions that the investigator deems unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year Disease-Free Survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease-Free Survival, DFS;2-year Disease-Free Survival rate;2-year and 3-year overall survival rates; | — |
Countries
China
Contacts
Public ContactWang Hongyan
The Fourth Hospital of Hebei Medical University
Outcome results
None listed